Creating a vaccine to protect against the dangerous fungus Candida auris.
Official title: Development of an alpha-1 phosphate mannan vaccine against the emerging fungal pathogen Candida auris.
Funded at East Tennessee State University · NIH-10915405 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from Candida auris, a tough fungus that can cause serious infections, by using a part of the fungus to boost the immune system and keep you safe.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | East Tennessee State University NIH-funded |
| Lab location | 1 site (Johnson City, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $187,500 |
| NIH project number | 5R21AI173607-02 |
| Project ID | NIH-10915405 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for Candida auris infections, such as those in healthcare settings or with compromised immune systems.
✕Less likely to help
Patients who are not at risk for Candida auris infections or those who do not have underlying health conditions may not benefit from this research.
What this research studies
This research focuses on developing a vaccine specifically targeting Candida auris, a fungal pathogen known for its resistance to antifungal treatments and high mortality rates. The approach involves utilizing mannan, a component found on the surface of the fungus, to stimulate the immune system and provide protection against infections. By addressing the unique challenges posed by C. auris, the research aims to prevent its spread and reduce the severe health risks associated with this pathogen.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces infections and mortality rates associated with Candida auris.
How similar studies have gone: While research on vaccines for fungal pathogens is ongoing, the specific approach targeting Candida auris is relatively novel and has not been extensively tested.
Where this research is happening
-
East Tennessee State University
Johnson City, United States Active
Researchers
- Principal investigator: Williams, David L. — East Tennessee State University
- Study coordinator: Williams, David L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.